BICO Group AB engages in the provision of technologies, products, and services to create, understand, and master biology. The company is headquartered in Goeteborg, Vastra Gotalands and currently employs 567 full-time employees. The company went IPO on 2016-11-03. The firm focuses on the application areas of bioprinting, multiomics, cell line development, and diagnostics. The firm develops and markets technologies that enable researchers in the life sciences to culture cells in 3D, perform high-throughput drug screening and print human tissues and organs for the medical, pharmaceutical, and cosmetic industries. The Company’s operations divided in two segments: The Industrial Solutions segment that offers products within precision dispensing and biosensor technology for industrial customers, which make a high-capacity contribution to customers production; and The Laboratory Solutions segment that offers 3Dprinters, single- cell and liquid- dispensing instruments as well as services and consumables related to these products.
最新の財務諸表(Form-10K)によると、BICO Group ABの総資産は$3,696で、純損失は$-1,088です。
CLLKFの主要な財務比率は何ですか?
BICO Group ABの流動比率は1.89、純利益率は-72.67、1株当たり売上高は$21.21です。
BICO Group ABの収益はセグメントまたは地域別にどのように分けられていますか?
BICO Group AB の最大収益セグメントは Life Science Solutions で、最新の利益発表における収益は 1,009,100,000 です。地域別に見ると、United States が BICO Group AB の主要市場であり、収益は 1,162,800,000 です。